文献速递心脑血管急症重症综合管理与镇静镇痛

重组人MG53蛋白可减小创伤性脑损伤大型动物模型的脑损伤体积

Recombinant human MG53 protein attenuates brain lesion size in a large animal model of traumatic brain injury.
PubMed 文献 · J Trauma Acute Care Surg · 2022-07-15
一句话结论在猪控制性皮层撞击TBI模型中,静脉给予rhMG53 2 mg/kg使脑损伤体积小于生理盐水对照组。

本研究在40-45 kg约克夏猪中建立控制性皮层撞击创伤性脑损伤模型,每组n=5,随机接受重组人MG53蛋白2 mg/kg静脉给药或生理盐水对照,监测血流动力学、颅内压和脑氧合7小时。结果显示两组血流动力学参数相似,但rhMG53组脑损伤体积为2517±525.4 mm³,显著小于对照组的3646±740.1 mm³(p<0.05);治疗组TBI周围区域可检测到rhMG53,对照组缺失,且治疗组脑内Bcl-2和磷酸化GSK β水平上调。作者结论为静脉给予rhMG53可定位于脑损伤区域并显著减轻TBI后脑损伤体积。

要点

  • 在40-45 kg约克夏猪控制性皮层撞击TBI模型中,rhMG53组脑损伤体积2517±525.4 mm³,显著小于生理盐水对照组3646±740.1 mm³(p<0.05)。
  • rhMG53按2 mg/kg静脉给药,监测血流动力学、颅内压和脑氧合7小时,两组血流动力学参数相似。
  • 治疗组TBI周围区域可检测到rhMG53,生理盐水对照组未检测到。
  • 治疗组脑内Bcl-2和磷酸化GSK β水平上调,作为促存活通路激活标志物。

适用人群与场景

  • 40-45 kg约克夏猪,接受控制性皮层撞击创伤性脑损伤模型,每组n=5。

处置流程与药物剂量

  • 随机分为重组人MG53蛋白2 mg/kg静脉给药组或生理盐水对照组,监测血流动力学、颅内压和脑氧合7小时。

研究设计与关键结果

  • 研究类型:大型动物(猪)实验,每组n=5,随机分为rhMG53 2 mg/kg静脉给药组和生理盐水对照组。
  • 主要结果:rhMG53组脑损伤体积2517±525.4 mm³,显著小于对照组3646±740.1 mm³(p<0.05)。
  • 两组血流动力学参数相似;治疗组TBI周围区域检测到rhMG53,对照组缺失;治疗组脑内Bcl-2和磷酸化GSK β水平上调。

证据类型、等级与局限

  • 证据类型:大型动物实验(猪TBI模型),样本量每组n=5。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,静脉给予rhMG53可定位于脑损伤区域,并使TBI后脑损伤体积显著减小;该结果来自猪模型,原文未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: MG53, a member of the tripartite motif (TRIM) protein family, plays an essential role in cell membrane repair and promotes cell survival. Recent studies show that systemic delivery of recombinant human MG53 (rhMG53) protein markedly attenuates tissue injury/inflammation, and facilitates healing. This study was performed to test whether intravenous administration of rhMG53 protein would decrease the lesion size in a clinically relevant large animal model of traumatic brain injury (TBI).

METHOD: Yorkshire swine (40-45 kg; n = 5/group) were subjected to controlled cortical impact TBI and randomized to either: (1) rhMG53 protein (2 mg/kg, intravenous) or (2) normal saline control. Hemodynamics, intracranial pressure, and brain oxygenation were monitored for 7 hours. Brains were then harvested and sectioned into 5-mm slices and stained with 2,3,5-triphenyltetrazolium chloride to quantify the lesion size. Blood-brain barrier permeability of MG53 in the brain was determined by Western blot and immunohistochemistry. Bcl-2 and phospho-GSK β levels were measured as makers of prosurvival pathway activation.

RESULTS: Hemodynamic parameters were similar in both groups, but the lesion size in the rhMG53-treated group (2,517 ± 525.4 mm 3 ) was significantly ( p < 0.05) smaller than the control group (3,646 ± 740.1 mm 3 ). In the treated animals, rhMG53 was detected in the regions surrounding the TBI, but it was absent in the saline-treated control animals. Bcl-2 and phospho-GSK β levels in the brains were upregulated in the rhMG53-treated animals.

CONCLUSION: Intravenously administered rhMG53 localizes to the injured areas of the brain, with the treated animals demonstrating a significant attenuation in the brain lesion size following TBI.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Jin G, Ho JW, Keeney-Bonthrone TP, et al. Recombinant human MG53 protein attenuates brain lesion size in a large animal model of traumatic brain injury. J Trauma Acute Care Surg. 2022. PMID: 35838363. doi:10.1097/TA.0000000000003746

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。